Mai Capital Management Avadel Pharmaceuticals PLC Transaction History

Mai Capital Management

  • $10.1 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024
BUY
$12.55 - $17.22 $56,788 - $77,920
4,525 Added 4.23%
111,605 $1.89 Million
Q4 2023

Feb 09, 2024
BUY
$9.64 - $14.59 $596,301 - $902,493
61,857 Added 136.78%
107,080 $1.51 Million
Q3 2023

Nov 14, 2023
SELL
$10.3 - $15.99 $62,284 - $96,691
-6,047 Reduced 11.79%
45,223 $465,000
Q2 2023

Aug 02, 2023
BUY
$8.48 - $16.48 $434,769 - $844,929
51,270 New
51,270 $844,000

Others Institutions Holding AVDL

# of Institutions
8
Shares Held
1.07M
Call Options Held
0
Put Options Held
0
View Full List

About AVADEL PHARMACEUTICALS PLC

AVDL Quotes by TradingView
  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $661M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Mai Capital Management Portfolio

Follow Mai Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mai Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Mai Capital Management with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email